China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the successful completion of the first clinical treatment of an atrial fibrillation patient using its first-in-class HeartLight X3 laser ablation platform. The procedure was carried out at the Hainan branch of Shanghai’s Ruijin Hospital, marking a significant milestone in the company’s development of innovative medical technologies.
HeartLight X3: World’s Only Laser Ablation Product for Atrial Fibrillation
HeartLight X3 is the world’s only atrial fibrillation product for ring ablation treatment by laser. It earned marketing approval in the US in May 2020, with first and second-generation systems having completed over 15,000 clinical treatments. The HeartLight X3 laser ablation platform uses the unique RAPID mode to achieve accurate and continuous energy delivery. This is accomplished through the patented cardiac endoscope technology of direct tissue visualization, adjustable laser energy, and super-compliant balloon technology. These features reduce the manual overlapping of individual lesions and more accurately perform complete pulmonary vein isolation.
Core Strategic Fields and Regulatory Progress
The precise interventional diagnosis and treatment of cardio-cerebrovascular diseases is one of the core strategic fields of China Grand. The company has four such products approved in China. Additionally, its NOVASIGHT Hybrid is awaiting regulatory decisions in China, where HeartLight X3 has also been filed for marketing. This progress highlights Grand Pharmaceutical’s commitment to advancing medical technologies and improving patient outcomes in the treatment of atrial fibrillation and other cardio-cerebrovascular diseases.-Fineline Info & Tech
